Details of the Drug Combinations

General Information of This Drug (ID: DMK7IWL)

• Drug Name: Relugolix (DMK7IWL)
• Synonyms: 737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917

Indication

Prostate cancer; ICD 11: 2C82.0; Status: Approved [1]; Endometriosis; ICD 11: GA10; Status: Phase 3 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Relugolix + Panobinostat	DCT0CQT	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Relugolix + GSK2126458	DC3QS01	GSK2126458	DD2 (Cell Line: DD2)	[3]
Relugolix + Artemisinin	DC63A4D	Artemisinin	DD2 (Cell Line: DD2)	[3]
Relugolix + Chloroquine	DC43VPP	Chloroquine	DD2 (Cell Line: DD2)	[3]

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atorvastatin + Relugolix	DCBMFOS	Atorvastatin	Prostate Cancer	[4]
Itraconazole + Relugolix	DCTCVPY	Itraconazole	Prostate Cancer	[5]
Relugolix + Fluconazole	DCAIRXX	Fluconazole	Prostate Cancer	[4]
Relugolix + Ritonavir	DCEVAMU	Ritonavir	Prostate Cancer	[5]
Relugolix + Arn-509	DCRLSKB	Arn-509	Metastatic Castration-Resistant Prostate Cancer	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT02093390) A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
• [5] ClinicalTrials.gov (NCT05679388) A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
• [6] ClinicalTrials.gov (NCT04666129) Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer